Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

Launched by CASE COMPREHENSIVE CANCER CENTER · May 15, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how chemotherapy for acute leukemia affects the brain in children, teenagers, and young adults. Acute leukemia is a type of cancer that can develop quickly and includes conditions like acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Researchers want to use a special brain scan called Magnetic Resonance Fingerprinting (MRF) to see if there are any changes in the brain matter of participants during and after their treatment. They will also use a fun, game-like test on tablets to check memory and brain function. By comparing the scan results with the test scores, they hope to identify which patients might be at risk for brain function issues due to chemotherapy.

To be eligible for this study, participants must be between 0 and 30 years old and have been diagnosed with acute leukemia. They should be receiving treatment at specific hospitals or referred from other facilities. Participants need to understand the study and agree to take part, with special information provided for younger patients. It's important to note that individuals who have already started chemotherapy for more than two weeks or have certain medical devices, like pacemakers, won't be able to participate. Participants can expect a quick, non-invasive brain scan and a short, engaging cognitive test that takes about 20 minutes to complete. This study aims to improve the understanding of potential brain side effects from chemotherapy and help find ways to prevent them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age range: 0 - 30 years
• • Participants from University Hospitals Rainbow Babies \& Children's Hospital, UH Seidman Cancer Center, and participants referred from outside facilities diagnosed with acute leukemia.
• • Meets diagnostic criteria for acute leukemia including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and myeloproliferative neoplasm/leukemia.
• • Participants must have the ability to understand and the willingness to sign a written informed consent document. Participants who are 14 years and older must have the ability to understand and the willingness to sign a written informed consent document. Participants who are between the ages of 7 to 13 will be given an information sheet that explains the study to them. The information sheet may be used for study participants between the ages of 14-17 if it would better inform the child about the nature and procedures that will undergo as a participant in the study.
• Exclusion Criteria:
• • Individuals that are \>2 weeks into the induction chemotherapy for acute leukemia.
• • Individuals with either a heart pacemaker, heart defibrillator, metal in the eye, some types of metal elsewhere within the body such as certain surgical clips for aneurysms in the head, heart valve prostheses, electrodes, some other implanted devices, or any other MRI contraindication